pI: 6.4118 |
Length (AA): 402 |
MW (Da): 45217 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 8 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 189 | 4glt (A) | 3 | 200 | 14.00 | 0.015 | 0.87 | 0.662449 | -0.53 |
1 | 203 | 4o7h (A) | 4 | 219 | 12.00 | 0.26 | 1 | 0.677275 | -0.4 |
3 | 78 | 1yq1 (A) | 24 | 90 | 40.00 | 0.016 | 0.71 | 0.464255 | 0.53 |
12 | 190 | 4gf0 (B) | 10 | 204 | 16.00 | 0 | 1 | 0.711574 | -0.59 |
14 | 211 | 2c3n (A) | 18 | 233 | 21.00 | 0 | 1 | 0.704837 | -0.36 |
29 | 78 | 4q5f (A) | 45 | 89 | 47.00 | 0.39 | 0.47 | 0.517578 | 0.01 |
36 | 182 | 3ein (A) | 53 | 191 | 25.00 | 0.000035 | 0.92 | 0.648872 | -0.34 |
237 | 401 | 1pbu (A) | 277 | 436 | 31.00 | 0 | 1 | 0.789748 | -0.9 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_127580)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G09640 | elongation factor EF-1 gamma subunit |
Arabidopsis thaliana | AT1G57720 | elongation factor EF-1 gamma subunit |
Babesia bovis | BBOV_II000890 | hypothetical protein |
Brugia malayi | Bm1_51865 | Elongation factor 1 gamma, conserved domain containing protein |
Candida albicans | CaO19.2651 | one of three genes similar to S. cerevisiae translation elongation factor gamma-like genes TEF4 (YKL081W) and CAM1 (YPL048W) and |
Candida albicans | CaO19.10174 | one of three genes similar to S. cerevisiae translation elongation factor gamma-like genes TEF4 (YKL081W) and CAM1 (YPL048W) and |
Caenorhabditis elegans | CELE_F17C11.9 | Protein EEF-1G, isoform A |
Cryptosporidium hominis | Chro.70492 | elongation factor 1-gamma |
Cryptosporidium parvum | cgd7_4450 | elongation factor EF1-gamma (glutathione S-transferase family) |
Dictyostelium discoideum | DDB_G0282979 | elongation factor 1 gamma |
Drosophila melanogaster | Dmel_CG11901 | CG11901 gene product from transcript CG11901-RC |
Echinococcus granulosus | EgrG_000113800 | eukaryotic translation elongation factor 1 |
Entamoeba histolytica | EHI_119540 | eukaryotic translation elongation factor 1 gamma, putative |
Echinococcus multilocularis | EmuJ_000113800 | eukaryotic translation elongation factor 1 |
Giardia lamblia | GL50803_12102 | Elongation factor 1-gamma |
Homo sapiens | ENSG00000254772 | eukaryotic translation elongation factor 1 gamma |
Leishmania braziliensis | LbrM.09.1020 | elongation factor-1 gamma |
Leishmania donovani | LdBPK_091030.1 | elongation factor-1 gamma |
Leishmania donovani | LdBPK_091020.1 | elongation factor-1 gamma |
Leishmania infantum | LinJ.09.1020 | elongation factor-1 gamma |
Leishmania infantum | LinJ.09.1030 | elongation factor-1 gamma |
Leishmania major | LmjF.09.0970 | elongation factor-1 gamma |
Leishmania mexicana | LmxM.09.0970 | elongation factor-1 gamma |
Loa Loa (eye worm) | LOAG_06167 | hypothetical protein |
Mus musculus | ENSMUSG00000071644 | eukaryotic translation elongation factor 1 gamma |
Mus musculus | 101055956 | predicted gene, 29753 |
Neospora caninum | NCLIV_064580 | hypothetical protein |
Oryza sativa | 4328753 | Os02g0220600 |
Oryza sativa | 4328752 | Os02g0220500 |
Oryza sativa | 4341354 | Os06g0571400 |
Plasmodium berghei | PBANKA_1352000 | elongation factor 1-gamma, putative |
Plasmodium falciparum | PF3D7_1338300 | elongation factor 1-gamma, putative |
Plasmodium knowlesi | PKNH_1263000 | elongation factor 1-gamma, putative |
Plasmodium vivax | PVX_082845 | elongation factor 1-gamma, putative |
Plasmodium yoelii | PY07121 | probable elongation factor 1-gamma 1 |
Saccharomyces cerevisiae | YPL048W | Cam1p |
Saccharomyces cerevisiae | YKL081W | Tef4p |
Schistosoma japonicum | Sjp_0042030 | ko:K03233 elongation factor EF-1 gamma subunit, putative |
Schistosoma mansoni | Smp_083410 | elongation factor 1-gamma |
Schmidtea mediterranea | mk4.022542.00 | |
Schmidtea mediterranea | mk4.009494.01 | |
Schmidtea mediterranea | mk4.003090.01 | Probable elongation factor 1-gamma |
Schmidtea mediterranea | mk4.000124.02 | |
Schmidtea mediterranea | mk4.017970.00 | |
Schmidtea mediterranea | mk4.004456.01 | |
Schmidtea mediterranea | mk4.034708.00 | |
Schmidtea mediterranea | mk4.008106.01 | |
Trypanosoma brucei gambiense | Tbg972.11.14570 | elongation factor 1 gamma, putative |
Trypanosoma brucei gambiense | Tbg972.11.14720 | elongation factor 1 gamma, putative |
Trypanosoma brucei | Tb927.11.13190 | elongation factor 1 gamma, putative |
Trypanosoma brucei | Tb427tmp.01.4750 | elongation factor 1 gamma, putative |
Trypanosoma congolense | TcIL3000.11.13550 | elongation factor 1 gamma, putative |
Trypanosoma congolense | TcIL3000_0_43470 | elongation factor 1 gamma, putative |
Trypanosoma congolense | TcIL3000.11.13470 | elongation factor 1 gamma, putative |
Trypanosoma cruzi | TcCLB.510163.20 | elongation factor 1-gamma (EF-1-gamma), putative |
Trypanosoma cruzi | TcCLB.508521.81 | elongation factor 1-gamma (EF-1-gamma), putative |
Toxoplasma gondii | TGME49_300140 | elongation factor 1-gamma, putative |
Theileria parva | TP04_0492 | elongation factor 1 gamma, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.4660 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.4660 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.4660 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.01.4660 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb11.01.4750 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.4750 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.4750 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.01.4750 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F17C11.9 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_F17C11.9 | Caenorhabditis elegans | slow growth | wormbase |
CELE_F17C11.9 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1352000 | Plasmodium berghei | Essential | plasmo |
TGME49_300140 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.